EUVIMEDEUVIMED entdecken
Open Access

High-fidelity PAMless base editing of hematopoietic stem cells to treat chronic granulomatous disease

Vera Bzhilyanskaya iD, Linyuan Ma iD, Siyuan Liu, Lauren R Fox iD, Madelynn N Whittaker iD, Ronald J Meis iD, Uimook Choi, Amanda Lawson iD, Michelle Ma iD, Narda Theobald iD, Sandra Burkett iD, Colin L Sweeney iD und 8 weitere

Science Translational Medicine · 2024

DOI: 10.1126/scitranslmed.adj6779 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2024. Verfasst von Vera Bzhilyanskaya und 19 weiteren Autor:innen. Beteiligte Einrichtung: Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National In…. Hauptthemen laut MEDLINE: Granulomatous Disease, Chronic, Gene Editing, Hematopoietic Stem Cells, Mutation. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Intramural NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

X-linked chronic granulomatous disease (X-CGD) is an inborn error of immunity (IEI) resulting from genetic mutations in the cytochrome b-245 beta chain ( CYBB ) gene. The applicability of base editors (BEs) to correct mutations that cause X-CGD is constrained by the requirement of Cas enzymes to recognize specific protospacer adjacent motifs (PAMs). Our recently engineered PAMless Cas enzyme, SpRY, can overcome the PAM limitation. However, the efficiency, specificity, and applicability of SpRY-based BEs to correct mutations in human hematopoietic stem and progenitor cells (HSPCs) have not been thoroughly examined. Here, we demonstrated that the adenine BE ABE8e-SpRY can access a range of target sites in HSPCs to correct mutations causative of X-CGD. For the prototypical X-CGD mutation CYBB c.676C>T, ABE8e-SpRY achieved up to 70% correction, reaching efficiencies greater than three-and-one-half times higher than previous CRISPR nuclease and donor template approaches. We profiled potential off-target DNA edits, transcriptome-wide RNA edits, and chromosomal perturbations in base-edited HSPCs, which together revealed minimal off-target or bystander edits. Edited alleles persisted after transplantation of the base-edited HSPCs into immunodeficient mice. Together, these investigational new drug–enabling studies demonstrated efficient and precise correction of an X-CGD mutation with PAMless BEs, supporting a first-in-human clinical trial (NCT06325709) and providing a potential blueprint for treatment of other IEI mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Granulomatous Disease, ChronicGene EditingHematopoietic Stem CellsMutationHumansAnimalsNADPH Oxidase 2MiceCRISPR-Cas SystemsHematopoietic Stem Cell Transplantation

Substanzen

NADPH Oxidase 2

Autor:innen und Institutionen

  • Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Department of Pathology, Harvard Medical School, Boston, MA 02115, USA.
  • Molecular Cytogenetic Core Facility, Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.
  • CELLSCRIPT, Madison, WI 53713, USA.

ORCID-Profile: Vera Bzhilyanskaya, Linyuan Ma, Lauren R Fox, Madelynn N Whittaker, Ronald J Meis, Amanda Lawson, Michelle Ma, Narda Theobald, Sandra Burkett, Colin L Sweeney, Cicera R Lazzarotto, Shengdar Q Tsai, Xiaolin Wu, Harry L Malech, Benjamin P Kleinstiver, Suk See De Ravin

Förderung

  • NCI NIH HHS
  • Intramural NIH HHS
  • NHLBI NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Bzhilyanskaya, V., Ma, L., Liu, S., Fox, L. R., Whittaker, M. N., Meis, R. J., Choi, U., Lawson, A., Ma, M., Theobald, N., Burkett, S., Sweeney, C. L., Lazzarotto, C. R., Tsai, S. Q., Lack, J. B., Wu, X., Dahl, G. A., Malech, H. L., Kleinstiver, B. P., & De Ravin, S. S. (2024). High-fidelity PAMless base editing of hematopoietic stem cells to treat chronic granulomatous disease. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adj6779

Vancouver

Bzhilyanskaya V, Ma L, Liu S, Fox LR, Whittaker MN, Meis RJ, et al. High-fidelity PAMless base editing of hematopoietic stem cells to treat chronic granulomatous disease. Science Translational Medicine. 2024. doi:10.1126/scitranslmed.adj6779

BibTeX
@article{Bzhilyanskaya2024,
  author = {Bzhilyanskaya, Vera and Ma, Linyuan and Liu, Siyuan and Fox, Lauren R and Whittaker, Madelynn N and Meis, Ronald J and Choi, Uimook and Lawson, Amanda and Ma, Michelle and Theobald, Narda and Burkett, Sandra and Sweeney, Colin L and Lazzarotto, Cicera R and Tsai, Shengdar Q and Lack, Justin B and Wu, Xiaolin and Dahl, Gary A and Malech, Harry L and Kleinstiver, Benjamin P and De Ravin, Suk See},
  title = {High-fidelity PAMless base editing of hematopoietic stem cells to treat chronic granulomatous disease},
  journal = {Science Translational Medicine},
  year = {2024},
  doi = {10.1126/scitranslmed.adj6779}
}
Kostenlos starten →